文献速递炎症性肠病

识别炎症性肠病并发症高风险与低风险患者

Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-11-25

炎症性肠病患者的临床表现和结局差异很大,治疗策略已转向早期干预以预防不可逆损伤。当前治疗决策多基于症状或疾病活动度,而未纳入纵向病程评估。因此,开发将患者分层为并发症低风险与高风险的方法,对优化治疗选择至关重要。

要点

  • IBD治疗策略已转向早期干预,以预防不可逆损伤。
  • 当前治疗分型多基于症状,未纳入纵向病程评估。
  • 需开发并发症风险分层方法以指导治疗选择。

核心结论

  • 开发将IBD患者分层为并发症低风险与高风险的方法,是当前和未来治疗IBD的重要方面。

主要发现

  • IBD患者的临床表现和临床结局存在差异。
  • 过去十年IBD治疗策略已转向在病程早期、不可逆损伤发生前进行治疗。
  • mild、moderate或severe的治疗方案通常基于当前症状或疾病活动度评估,未包含对患者病程(包括既往并发症和手术)的纵向评估。
  • 最优治疗决策应综合考虑既往疾病活动度和并发症以及预测的未来病程。

临床怎么用

  • 为个体患者制定治疗计划时,近期目标是治疗当前疾病活动以缓解症状。
  • 长期目标是预防疾病因并发症而进展。
  • 应选择合适患者接受合适治疗,因并非所有患者都会进展为复杂病程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People with Crohn's disease and ulcerative colitis have varying presentations and clinical consequences of their disease. Patients commonly ask about their prognosis, and what this diagnosis means for them. They are asking their clinicians to predict the future. The importance of predicting the course of any disease is to guide patient expectations and to guide treatment decisions. In the past decade the strategy of inflammatory bowel disease (IBD) treatment has shifted to treat patients earlier in the course of their disease, before irreversible damage occurs. Treatment approaches for disease categorized as mild, moderate or severe has most often been based on a current assessment of symptoms or disease activity without including a longitudinal assessment of a patient's disease course including past disease complications and surgeries. While a patient's current disease activity most typically drives these treatment decisions, optimally, treatment decisions would be made accounting for past disease activity and complications and the predicted future disease course. When developing a treatment plan for an individual patient, the immediate goal is to treat the current disease activity for relief of symptoms, and the long-term goal is to prevent progression of their disease due to complications. Since not all patients will progress to a complicated disease course, it is important to be able to select the right patients for the right therapy. Therefore, developing methods of stratifying patients into low-risk versus high-risk of complications will be an important aspect of treating IBD now and in the future.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Siegel CA, Bernstein CN. Identifying Patients With Inflammatory Bowel Diseases at High vs Low Risk of Complications. Clin Gastroenterol Hepatol. 2019. PMID: 31778805. doi:10.1016/j.cgh.2019.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。